Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyFluoxymesterone
Identification
- Name
- Fluoxymesterone
- Accession Number
- DB01185 (APRD00981)
- Type
- Small Molecule
- Groups
- Approved, Illicit
- Description
An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. [PubChem]
- Structure
Structure for DB01185 (Fluoxymesterone)
- Synonyms
- 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one
- 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone
- 17α-Methyl-9α-fluoro-11β-hydroxytesterone
- 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one
- 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone
- Fluoximesterona
- Fluoxymesteronum
- Testosterone, 9-fluoro-11beta-hydroxy-17-methyl-
- External IDs
- NSC-12165
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Halotestin Tablet 5 mg Oral Pfizer 1962-12-31 2006-08-02 Canada 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Androxy Tablet 10 mg/1 Oral Upsher Smith Laboratories, Llc 1983-10-21 Not applicable US 
- International/Other Brands
- Ora-Testryl (Bristol-Myers Squibb) / Testoral (Midy) / U-Gono (Upjohn) / UItandren (Ciba)
- Categories
- UNII
- 9JU12S4YFY
- CAS number
- 76-43-7
- Weight
- Average: 336.4409
Monoisotopic: 336.210072999 - Chemical Formula
- C20H29FO3
- InChI Key
- YLRFCQOZQXIBAB-RBZZARIASA-N
- InChI
- InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1
- IUPAC Name
- (1R,2S,10S,11S,14S,15S,17S)-1-fluoro-14,17-dihydroxy-2,14,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
- SMILES
- [H][[email protected]@]12CC[[email protected]](C)(O)[[email protected]@]1(C)C[[email protected]](O)[[email protected]@]1(F)[[email protected]@]2([H])CCC2=CC(=O)CC[[email protected]]12C
Pharmacology
- Indication
In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.
- Structured Indications
- Pharmacodynamics
Fluoxymesterone is a synthetic androgen, or male hormone, similar to testosterone. Fluoxymesterone works by attaching itself to androgen receptors; this causes it to interact with the parts of the cell involved in the making of proteins. It may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells, stimulating cells that cause male sexual characteristics, and stimulating the production of red blood cells.
- Mechanism of action
Fluoxymesterone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, fluoxymesterone binds to the androgen receptor. It produces retention of nitrogen, sodium, potassium, and phosphorus; increases protein anabolism; decreases amino acid catabolism and decreased urinary excretion of calcium. The antitumour activity of fluoxymesterone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.
Target Actions Organism AAndrogen receptor agonistHuman AEstrogen receptor alpha antagonistHuman AProlactin receptor antagonistHuman UGlucocorticoid receptor antagonistHuman UCorticosteroid 11-beta-dehydrogenase isozyme 2 inhibitorHuman - Absorption
Oral absorption is less than 44%.
- Volume of distribution
- Not Available
- Protein binding
Very high (99%) with 80% to sex hormone binding globulin, 19% to albumin.
- Metabolism
Presence of 17-alpha alkyl group reduces susceptibility to hepatic enzyme degradation, which slows metabolism and allows oral administration. Inactivation of testosterone occurs primarily in the liver
- Route of elimination
- Not Available
- Half life
9.2 hours
- Clearance
- Not Available
- Toxicity
Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone 16-Bromoepiandrosterone may increase the fluid retaining activities of Fluoxymesterone. Investigational 19-norandrostenedione 19-norandrostenedione may increase the fluid retaining activities of Fluoxymesterone. Experimental, Illicit 5-androstenedione 5-androstenedione may increase the fluid retaining activities of Fluoxymesterone. Experimental, Illicit Acarbose Fluoxymesterone may increase the hypoglycemic activities of Acarbose. Approved, Investigational Acenocoumarol Fluoxymesterone may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Albiglutide Fluoxymesterone may increase the hypoglycemic activities of Albiglutide. Approved Alclometasone Alclometasone may increase the fluid retaining activities of Fluoxymesterone. Approved Aldosterone Aldosterone may increase the fluid retaining activities of Fluoxymesterone. Experimental, Investigational Alogliptin Fluoxymesterone may increase the hypoglycemic activities of Alogliptin. Approved Amcinonide Amcinonide may increase the fluid retaining activities of Fluoxymesterone. Approved Androstenedione Androstenedione may increase the fluid retaining activities of Fluoxymesterone. Experimental, Illicit Anecortave Anecortave may increase the fluid retaining activities of Fluoxymesterone. Investigational anecortave acetate anecortave acetate may increase the fluid retaining activities of Fluoxymesterone. Investigational Atamestane Atamestane may increase the fluid retaining activities of Fluoxymesterone. Investigational Beclomethasone dipropionate Beclomethasone dipropionate may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Betamethasone Betamethasone may increase the fluid retaining activities of Fluoxymesterone. Approved, Vet Approved Bromocriptine Fluoxymesterone may increase the hypoglycemic activities of Bromocriptine. Approved, Investigational Budesonide Budesonide may increase the fluid retaining activities of Fluoxymesterone. Approved Canagliflozin Fluoxymesterone may increase the hypoglycemic activities of Canagliflozin. Approved Chlorpropamide Fluoxymesterone may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Ciclesonide Ciclesonide may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Clobetasol Clobetasol may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Clobetasol propionate Clobetasol propionate may increase the fluid retaining activities of Fluoxymesterone. Approved Clobetasone Clobetasone may increase the fluid retaining activities of Fluoxymesterone. Approved Clocortolone Clocortolone may increase the fluid retaining activities of Fluoxymesterone. Approved Clorindione Fluoxymesterone may increase the anticoagulant activities of Clorindione. Experimental Conestat alfa Fluoxymesterone may increase the thrombogenic activities of Conestat alfa. Approved, Investigational Cortexolone 17α-propionate Cortexolone 17α-propionate may increase the fluid retaining activities of Fluoxymesterone. Investigational Corticosterone Corticosterone may increase the fluid retaining activities of Fluoxymesterone. Experimental Cortisone acetate Cortisone acetate may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Cyclosporine Fluoxymesterone may increase the hepatotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Dapagliflozin Fluoxymesterone may increase the hypoglycemic activities of Dapagliflozin. Approved Deflazacort Deflazacort may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Desonide Desonide may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Desoximetasone Desoximetasone may increase the fluid retaining activities of Fluoxymesterone. Approved Desoxycorticosterone acetate Desoxycorticosterone acetate may increase the fluid retaining activities of Fluoxymesterone. Approved Desoxycorticosterone Pivalate Desoxycorticosterone Pivalate may increase the fluid retaining activities of Fluoxymesterone. Experimental, Vet Approved Dexamethasone Dexamethasone may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Dexamethasone isonicotinate may increase the fluid retaining activities of Fluoxymesterone. Vet Approved Dicoumarol Fluoxymesterone may increase the anticoagulant activities of Dicoumarol. Approved Diflorasone Diflorasone may increase the fluid retaining activities of Fluoxymesterone. Approved Difluocortolone Difluocortolone may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational, Withdrawn Difluprednate Difluprednate may increase the fluid retaining activities of Fluoxymesterone. Approved Diphenadione Fluoxymesterone may increase the anticoagulant activities of Diphenadione. Experimental Disopyramide Fluoxymesterone may increase the hypoglycemic activities of Disopyramide. Approved Dulaglutide Fluoxymesterone may increase the hypoglycemic activities of Dulaglutide. Approved, Investigational Empagliflozin Fluoxymesterone may increase the hypoglycemic activities of Empagliflozin. Approved Equilenin Equilenin may increase the fluid retaining activities of Fluoxymesterone. Experimental Equilin Equilin may increase the fluid retaining activities of Fluoxymesterone. Approved Estrone Estrone may increase the fluid retaining activities of Fluoxymesterone. Approved Estrone sulfate Estrone sulfate may increase the fluid retaining activities of Fluoxymesterone. Approved Ethyl biscoumacetate Fluoxymesterone may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Exenatide Fluoxymesterone may increase the hypoglycemic activities of Exenatide. Approved, Investigational Fluasterone Fluasterone may increase the fluid retaining activities of Fluoxymesterone. Investigational Fludrocortisone Fludrocortisone may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Fluindione Fluoxymesterone may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumethasone Flumethasone may increase the fluid retaining activities of Fluoxymesterone. Approved, Vet Approved Flunisolide Flunisolide may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Fluocinolone Acetonide Fluocinolone Acetonide may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational, Vet Approved Fluocinonide Fluocinonide may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Fluocortolone Fluocortolone may increase the fluid retaining activities of Fluoxymesterone. Approved, Withdrawn Fluorometholone Fluorometholone may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Fluprednidene Fluprednidene may increase the fluid retaining activities of Fluoxymesterone. Approved, Withdrawn Fluprednisolone Fluprednisolone may increase the fluid retaining activities of Fluoxymesterone. Approved Flurandrenolide Flurandrenolide may increase the fluid retaining activities of Fluoxymesterone. Approved Fluticasone furoate Fluticasone furoate may increase the fluid retaining activities of Fluoxymesterone. Approved Fluticasone propionate Fluticasone propionate may increase the fluid retaining activities of Fluoxymesterone. Approved Formestane Formestane may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational, Withdrawn Gliclazide Fluoxymesterone may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Fluoxymesterone may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Fluoxymesterone may increase the hypoglycemic activities of Glipizide. Approved, Investigational Glyburide Fluoxymesterone may increase the hypoglycemic activities of Glyburide. Approved Halcinonide Halcinonide may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational, Withdrawn HE3286 HE3286 may increase the fluid retaining activities of Fluoxymesterone. Investigational Human C1-esterase inhibitor Fluoxymesterone may increase the thrombogenic activities of Human C1-esterase inhibitor. Approved Hydrocortisone Hydrocortisone may increase the fluid retaining activities of Fluoxymesterone. Approved, Vet Approved Insulin Aspart Fluoxymesterone may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Fluoxymesterone may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Fluoxymesterone may increase the hypoglycemic activities of Insulin Glargine. Approved Insulin Glulisine Fluoxymesterone may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Fluoxymesterone may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Fluoxymesterone may increase the hypoglycemic activities of Insulin Lispro. Approved Istaroxime Istaroxime may increase the fluid retaining activities of Fluoxymesterone. Investigational Liraglutide Fluoxymesterone may increase the hypoglycemic activities of Liraglutide. Approved Loteprednol Loteprednol may increase the fluid retaining activities of Fluoxymesterone. Approved ME-609 ME-609 may increase the fluid retaining activities of Fluoxymesterone. Investigational Mecasermin Fluoxymesterone may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Medrysone Medrysone may increase the fluid retaining activities of Fluoxymesterone. Approved Melengestrol Melengestrol may increase the fluid retaining activities of Fluoxymesterone. Vet Approved Metformin Fluoxymesterone may increase the hypoglycemic activities of Metformin. Approved Methylprednisolone Methylprednisolone may increase the fluid retaining activities of Fluoxymesterone. Approved, Vet Approved Mifepristone Fluoxymesterone may increase the hypoglycemic activities of Mifepristone. Approved, Investigational Miglitol Fluoxymesterone may increase the hypoglycemic activities of Miglitol. Approved Mometasone Mometasone may increase the fluid retaining activities of Fluoxymesterone. Approved, Vet Approved Nateglinide Fluoxymesterone may increase the hypoglycemic activities of Nateglinide. Approved, Investigational NCX 1022 NCX 1022 may increase the fluid retaining activities of Fluoxymesterone. Investigational Oleoyl-estrone Oleoyl-estrone may increase the fluid retaining activities of Fluoxymesterone. Investigational Paramethasone Paramethasone may increase the fluid retaining activities of Fluoxymesterone. Approved Pentamidine Fluoxymesterone may increase the hypoglycemic activities of Pentamidine. Approved, Investigational Phenindione Fluoxymesterone may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Fluoxymesterone may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Pioglitazone Fluoxymesterone may increase the hypoglycemic activities of Pioglitazone. Approved, Investigational Pramlintide Fluoxymesterone may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Prasterone Prasterone may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational, Nutraceutical Prasterone sulfate Prasterone sulfate may increase the fluid retaining activities of Fluoxymesterone. Investigational Prednicarbate Prednicarbate may increase the fluid retaining activities of Fluoxymesterone. Approved, Investigational Prednisolone Prednisolone may increase the fluid retaining activities of Fluoxymesterone. Approved, Vet Approved Prednisone Prednisone may increase the fluid retaining activities of Fluoxymesterone. Approved, Vet Approved Pregnenolone Pregnenolone may increase the fluid retaining activities of Fluoxymesterone. Approved, Experimental, Investigational Quinine Fluoxymesterone may increase the hypoglycemic activities of Quinine. Approved Repaglinide Fluoxymesterone may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Rimexolone Rimexolone may increase the fluid retaining activities of Fluoxymesterone. Approved Rosiglitazone Fluoxymesterone may increase the hypoglycemic activities of Rosiglitazone. Approved, Investigational Saxagliptin Fluoxymesterone may increase the hypoglycemic activities of Saxagliptin. Approved Sitagliptin Fluoxymesterone may increase the hypoglycemic activities of Sitagliptin. Approved, Investigational Sulfadiazine Fluoxymesterone may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole Fluoxymesterone may increase the hypoglycemic activities of Sulfamethoxazole. Approved Sulfisoxazole Fluoxymesterone may increase the hypoglycemic activities of Sulfisoxazole. Approved, Vet Approved Sunitinib Fluoxymesterone may increase the hypoglycemic activities of Sunitinib. Approved, Investigational Tioclomarol Fluoxymesterone may increase the anticoagulant activities of Tioclomarol. Experimental Tixocortol Tixocortol may increase the fluid retaining activities of Fluoxymesterone. Approved, Withdrawn Tolazamide Fluoxymesterone may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide Fluoxymesterone may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Triamcinolone Triamcinolone may increase the fluid retaining activities of Fluoxymesterone. Approved, Vet Approved Ulobetasol Ulobetasol may increase the fluid retaining activities of Fluoxymesterone. Approved Warfarin Fluoxymesterone may increase the anticoagulant activities of Warfarin. Approved - Food Interactions
- Take with food.
References
- Synthesis Reference
U.S. Patent 2,793,218 U.S. Patent 2,813,881
- General References
- Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A: An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5. [PubMed:17023534]
- External Links
- Human Metabolome Database
- HMDB0015316
- KEGG Drug
- D00327
- PubChem Compound
- 6446
- PubChem Substance
- 46508867
- ChemSpider
- 6205
- BindingDB
- 18189
- ChEBI
- 5120
- ChEMBL
- CHEMBL1445
- Therapeutic Targets Database
- DAP000904
- PharmGKB
- PA164744518
- IUPHAR
- 2861
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Fluoxymesterone
- ATC Codes
- G03BA01 — Fluoxymesterone
- MSDS
- Download (75.7 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Terminated Treatment Metastatic Breast Cancer (MBC) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Major Pharmaceuticals
- Qualitest
- Spectrum Pharmaceuticals
- USL Pharma Inc.
- Valeant Ltd.
- Dosage forms
Form Route Strength Tablet Oral 10 mg/1 Tablet Oral 5 mg - Prices
Unit description Cost Unit Fluoxymesterone powder 391.79USD g Android 10 mg capsule 11.35USD each DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 265 U.S. Patent 2,793,218 U.S. Patent 2,813,881 water solubility 67.5 mg/L Not Available logP 2.38 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 0.0452 mg/mL ALOGPS logP 2.5 ALOGPS logP 2.38 ChemAxon logS -3.9 ALOGPS pKa (Strongest Acidic) 13.6 ChemAxon pKa (Strongest Basic) -3 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 57.53 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 90.19 m3·mol-1 ChemAxon Polarizability 36.63 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9633 Caco-2 permeable + 0.8586 P-glycoprotein substrate Substrate 0.7505 P-glycoprotein inhibitor I Non-inhibitor 0.7583 P-glycoprotein inhibitor II Non-inhibitor 0.87 Renal organic cation transporter Non-inhibitor 0.8136 CYP450 2C9 substrate Non-substrate 0.862 CYP450 2D6 substrate Non-substrate 0.8773 CYP450 3A4 substrate Substrate 0.7669 CYP450 1A2 substrate Non-inhibitor 0.9041 CYP450 2C9 inhibitor Non-inhibitor 0.8159 CYP450 2D6 inhibitor Non-inhibitor 0.9286 CYP450 2C19 inhibitor Non-inhibitor 0.917 CYP450 3A4 inhibitor Non-inhibitor 0.8354 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8585 Ames test Non AMES toxic 0.8777 Carcinogenicity Non-carcinogens 0.9242 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.7028 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.943 hERG inhibition (predictor II) Non-inhibitor 0.5784
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Mass Spectrum (Electron Ionization) MS splash10-006x-5951000000-4c37d94fe4ed0b343941 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Androstane steroids
- Direct Parent
- Androgens and derivatives
- Alternative Parents
- Halogenated steroids / 3-oxo delta-4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-4-steroids / Cyclohexenones / Tertiary alcohols / Secondary alcohols / Fluorohydrins / Cyclic alcohols and derivatives show 4 more
- Substituents
- Androgen-skeleton / 3-oxo-delta-4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / 9-halo-steroid / Halo-steroid / Hydroxysteroid show 20 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 11beta-hydroxy steroid, 3-oxo Delta(4)-steroid, 17beta-hydroxy steroid, fluorinated steroid, anabolic androgenic steroid (CHEBI:5120) / C19 steroids (androgens) and derivatives (LMST02020025)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 98987.9 Da
References
- Fernandez L, Chirino R, Boada LD, Navarro D, Cabrera N, del Rio I, Diaz-Chico BN: Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes. Endocrinology. 1994 Mar;134(3):1401-8. [PubMed:8119180]
- Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ: Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology. 1989 Mar;124(3):1576-8. [PubMed:2521824]
- Smallridge RC, Vigersky R, Glass AR, Griffin JE, White BJ, Eil C: Androgen receptor abnormalities in identical twins with oligospermia. Clinical and biochemical studies. Am J Med. 1984 Dec;77(6):1049-54. [PubMed:6439037]
- Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A: An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5. [PubMed:17023534]
- Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM: Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol. 1999 Mar;13(3):440-54. [PubMed:10077001]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA: Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006 Jul;98(2):217-22. Epub 2006 Mar 15. [PubMed:16538529]
- Sledge GW Jr, Hu P, Falkson G, Tormey D, Abeloff M: Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol. 2000 Jan;18(2):262-6. [PubMed:10637238]
- Pearson OH, Manni A, Arafah BM: Antiestrogen treatment of breast cancer: an overview. Cancer Res. 1982 Aug;42(8 Suppl):3424s-3429s. [PubMed:7044524]
- Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF: Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May;14(5):1589-98. [PubMed:8622076]
- Swain SM, Steinberg SM, Bagley C, Lippman ME: Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer--a randomized study. Breast Cancer Res Treat. 1988 Sep;12(1):51-7. [PubMed:3058238]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Protein homodimerization activity
- Specific Function
- This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and...
- Gene Name
- PRLR
- Uniprot ID
- P16471
- Uniprot Name
- Prolactin receptor
- Molecular Weight
- 69505.045 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Mayer M, Rosen F: Interaction of anabolic steroids with glucocorticoid receptor sites in rat muscle cytosol. Am J Physiol. 1975 Nov;229(5):1381-6. [PubMed:173192]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid binding
- Specific Function
- Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation...
- Gene Name
- HSD11B2
- Uniprot ID
- P80365
- Uniprot Name
- Corticosteroid 11-beta-dehydrogenase isozyme 2
- Molecular Weight
- 44126.06 Da
References
- Furstenberger C, Vuorinen A, Da Cunha T, Kratschmar DV, Saugy M, Schuster D, Odermatt A: The anabolic androgenic steroid fluoxymesterone inhibits 11beta-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol Sci. 2012 Apr;126(2):353-61. doi: 10.1093/toxsci/kfs022. Epub 2012 Jan 23. [PubMed:22273746]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Androgen binding
- Specific Function
- Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
- Gene Name
- SHBG
- Uniprot ID
- P04278
- Uniprot Name
- Sex hormone-binding globulin
- Molecular Weight
- 43778.755 Da
References
- Smallridge RC, Vigersky R, Glass AR, Griffin JE, White BJ, Eil C: Androgen receptor abnormalities in identical twins with oligospermia. Clinical and biochemical studies. Am J Med. 1984 Dec;77(6):1049-54. [PubMed:6439037]
- Pugeat MM, Dunn JF, Nisula BC: Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981 Jul;53(1):69-75. [PubMed:7195405]
- Vigersky RA, Easley RB, Loriaux DL: Effect of fluoxymesterone on the pituitary-gonadal axis: the role of testosterone-estradiol-binding globulin. J Clin Endocrinol Metab. 1976 Jul;43(1):1-9. [PubMed:947929]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 02:08